German pharma giant Bayer has agreed to offload its animal health unit to Elanco Animal Health for $7.6bn (£6.27bn) in a stock-cum-cash deal, in a move to focus on its life sciences business.
Gilead Sciences Canada announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults. Health Canada granted a Notice of Compliance for BIKTARVY in July 2018.
Alvogen announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe.
Pfizer announced the closing of its joint venture (JV) with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands.
Pfizer has agreed to merge its off-patent branded and generic established medicines business Upjohn with Mylan to establish a new global pharmaceutical company.
Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.
Jubilant Cadista Pharmaceuticals is voluntarily recalling one lot of Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/ 0.02mg, 28x3 Blister Pack/Carton to the consumer level.
Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, today announced the U.S. launch & commercial shipment of a generic version of Lyrica, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg.
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.
Sun Pharmaceutical Industries announced the U.S. launch of Ezallor Sprinkle (rosuvastatin) capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.